Emoled
- Company typePrivate
- Founded2016
- HeadquartersSesto Fiorentino, Italy
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Emoled firmographics
Firmographics- Name
- Emoled
- Legal name
- EMOLED SRL
- Website
- https://emoled.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Emoled industry classification
Industry- Product category
- Wound Care Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser) (HLAHADAC)
- akta.pro secondary industry
- Wound Care & Ulcer Management (HLAKACAN)
Keywords
Where Emoled is headquartered
LocationHeadquarters
- HQ city
- Sesto Fiorentino
- HQ country
- Italy
- HQ region
- Europe
Offices2 records
Markets served
Emoled business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- Medical Device Sales: Sale of the EmoLED Medical Device for skin lesion treatment, a proprietary LED-based photobiomodulation system targeting healthcare institutions and wound care specialists.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
Emoled product offering
Product offeringCore offering
Emoled manufactures and sells the EmoLED Medical Device, a proprietary LED-based photobiomodulation system that emits specific blue light wavelengths (410-430 nm) to treat skin lesions, including chronic and hard-to-heal wounds such as venous ulcers, diabetic foot ulcers, pressure ulcers, burns, and surgical wounds. The device is sold to healthcare institutions including hospitals, wound care clinics, burns centers, and plastic surgery practices, and is used as an adjunct to standard wound care treatments.
Product overview
Emoled offers a single unified medical device product: the EmoLED Medical Device. This is a blue light photobiomodulation system designed for the treatment of skin lesions and chronic wounds. The product operates by delivering specific wavelengths of blue light (410-430 nm) to modulate biological factors involved in the wound healing process, promoting tissue repair in difficult-to-heal wounds. The therapy is used as an adjunct to standard wound care treatments.
Differentiator
Problem solved
Functional benefit
Products and services
- EmoLED Medical Device A certified medical device using blue light photobiomodulation (410-430 nm wavelength) for the treatment of skin lesions, including chronic wounds (venous ulcers, diabetic foot ulcers, pressure ulcers), burns, and surgical wounds. The device delivers therapeutic blue light to promote wound healing by modulating biological factors involved in skin tissue repair processes, used as an adjunct to standard wound care treatments. Targeted at hospitals, wound care clinics, burns centers, and plastic/cosmetic surgery practices.
Quantifiable outcome
- 51.38% mean wound area reduction after 4 weeks of Blue Light treatment (p<0.001)
- +5 more outcomes
Companies that use Emoled
Customer profileNamed customers7 records
Segments2 records
Ideal customer profiles2 records
Emoled technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Emoled partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and major.
- LENS - European Laboratory for Non-Linear SpectroscopycoreLENS (Laboratorio Europeo di Spettroscopia Non Lineare) is a research partner collaborating with Emoled on the discovery that certain blue light wavelengths (410-430 nm) can modulate biological factors involved in skin tissue repair. Francesco Pavone from LENS serves as project coordinator for HyperProbe and explains photobiomodulation science.
- IFAC - Istituto di Fisica Applicata 'Nello Carrara'coreIFAC (Istituto di Fisica Applicata 'Nello Carrara') is part of the Italian research consortium collaborating with Emoled on photonic research and blue light technology development for medical applications.
- HyperProbe European ConsortiumcoreEmoled is partner of the HyperProbe European Consortium (Horizon Europe funded, grant agreement No 101071040) developing a novel cost-effective, transportable, compact optical imaging system for brain surgery guidance by 2027. Consortium includes: Università degli Studi di Firenze (coordinator), Technische Universität München, Université Lyon 1 Claude Bernard, CNRS, Azienda Ospedaliera Universitaria di Careggi, European Institute for Biomedical Imaging Research, Hospices Civils de Lyon, University College London.
- RehaCare Pty LtdmajorRehaCare Pty Ltd is the exclusive distributor of EmoLED Medical Device for Australia. They organized webinars with Emoled for wound care professionals and represented Emoled at Wounds Australia Conference (booth #27). Christian Stegle serves as Regional Director APAC for Emoled.
Scale indicators1 record
Recent moves6 records
Expansion highlights6 records
Emoled competitors and assessment
Company assessmentBroad incumbents
- ConvaTec: Major wound care company selling dressings, NPWT, and advanced wound therapies into the same hospital wound care units that Emoled targets with its blue light device.
- Cynosure (Hologic): Large medical aesthetic and dermatology device maker offering energy-based light and laser platforms, comparable as a broader incumbent in light-based clinical therapy categories.
- Smith & Nephew: Global medical device incumbent with a large advanced wound management portfolio (dressings, NPWT, biologics), addressing the same chronic wound customers and competing for hospital wound care budgets.
- Mölnlycke Health Care: Major wound care and surgical solutions provider whose dressings, antiseptics, and OR products are used by the same wound care and burns centers purchasing the EmoLED device.
- Coloplast: Established player in ostomy, continence, and advanced wound care, sharing Emoled's hospital wound care call points and representing a likely strategic comparator or acquirer profile.
- Lumenis: Global leader in energy-based medical devices including laser and light-based systems for aesthetics, dermatology, and surgical applications, overlapping with Emoled's photonic therapy modality at a much larger scale.
Direct peers
- THOR Photomedicine: Specialist manufacturer of photobiomodulation/phototherapy devices used in wound healing, pain management, and dermatology, competing head-to-head with Emoled in the clinical PBM segment using LED-based light sources.
- Photomedex: Medical device company offering light-based therapeutic systems for dermatology and wound indications, overlapping with Emoled's energy-based, light-driven wound healing approach.
- Klox Technologies: Developer of light-based bioPhotonic wound care and dermatology platforms, comparable to Emoled in using specific light spectra to drive tissue repair and chronic wound healing outcomes.
Emerging players
- MolecuLight: Provider of fluorescence-based wound imaging and point-of-care diagnostics used alongside wound care workflows, comparable as an enabling light/wound-care technology adopted by the same hospital specialists.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Emoled social profiles
Digital presenceEmoled financial estimates
Financial estimateRevenue estimate
Valuation estimate
Emoled leadership team
Management profileNumber of profiles
Profiles1 record
Emoled funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Emoled M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Emoled
What does Emoled do?
Emoled manufactures and sells the EmoLED Medical Device, a proprietary LED-based photobiomodulation system that emits specific blue light wavelengths (410-430 nm) to treat skin lesions, including chronic and hard-to-heal wounds such as venous ulcers, diabetic foot ulcers, pressure ulcers, burns, and surgical wounds. The device is sold to healthcare institutions including hospitals, wound care clinics, burns centers, and plastic surgery practices, and is used as an adjunct to standard wound care treatments.
Is Emoled a public or private company?
Emoled is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Emoled founded?
Emoled was founded in 2016. It employs 11 to 50 people.
Where is Emoled based?
Emoled is headquartered in Sesto Fiorentino, Italy, in the Europe region.
How does Emoled make money?
One revenue line is on record: medical Device Sales.
Who are Emoled's main competitors?
Broad incumbents on record are ConvaTec, Cynosure (Hologic), Smith & Nephew, Mölnlycke Health Care, Coloplast and Lumenis. Direct peers are THOR Photomedicine, Photomedex and Klox Technologies. MolecuLight is listed as an emerging player.
Does Emoled have an API?
No public API is recorded for Emoled.
What industry is Emoled in?
Emoled's product category is Wound Care Medical Devices. Its primary akta.pro industry code is HLAHADAC, Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser), with a secondary code of HLAKACAN, Wound Care & Ulcer Management. Its NAICS code is 334510 and its SIC code is 3845.